Chief Executive Officer
Jim is a seasoned medical device executive, most recently serving on the management board and as Chief Patent Counsel for Boston Scientific Neuromodulation. At Boston Jim provided strategic counsel and leadership to multiple divisions and functions in product development from concept, early innovation through commercialization. Jim is a Principal of Flair, LLC, which commercializes equine health products internationally. Jim practiced IP law in Minneapolis, representing start-up through Fortune 100 companies. He has served on the board or as an advisor for early-stage companies in the fields of medical products, cyber security, animal health, biotechnology and others. He is a veterinarian and co-founder of an equine veterinary hospital.
Chief Operating Officer/Chief Financial Officer
John has 30 years of experience in operating and building medical technology businesses. He is currently President of Business Development Advisors, Inc., providing corporate development services to early-stage and dynamic growth companies. He is also the Founder and Chairman of Twin Cities Angels (now on its third fund), an early stage investment firm in Minneapolis. John was previously CEO of Chameleon Scientific, leading a turnaround and raising $11 million. He is formerly Vice President of Corporate Development for St. Jude Medical now part of Abbott Laboratories (ABT). He has held leadership positions at Baxter Diagnostics, W.R. Grace & Co., and G.E. Venture Capital.
Chief Commercial Officer
Paul Rockley is an accomplished business development, sales and marketing executive with over 25 years in the ophthalmic medical device industry. His scope of product development and commercialization experience includes surgical capital equipment, implantable & viscoelastic devices as well as OTC tears. Prior to joining Biovisics Medical, Paul held senior leadership positions in business development and global commercialization at Eyenuk, Medical Care Corp, Abbott Laboratories Vision Division, Advanced Medical Optics (AMO) and Allergan.
Paul received his Honors B.Sc. from the University of Guelph (Canada) and his MBA in Healthcare from UC, Irvine.
Executive Board Member
Anthony Arnold is the CEO & Founder of Precys, a company that helps investors, innovators and early stage companies advance medical innovation. Anthony has almost 25 years of experience in the development and commercialization of high-technology medical devices in neuro, orthopedics, ENT and inflammatory diseases. Prior to founding Precys, Anthony served as CEO and President for SetPoint Medical; a pioneer in the field of bioelectronic medicine where he built a world-class team that delivered a revolutionary micro-implantable platform, novel therapeutic pathway tested in multiple human trials. Prior to joining SetPoint, Anthony held leadership positions with Boston Scientific Neuromodulation, Medtronic and Smith+ Nephew.
Medical Expert, Low Vision Optometry Advisor
Dr. Kammer is an optometrist who served as a faculty member and later in administration at Colleges of Optometry for 14 years. She holds a doctorate in Higher Education from Azusa Pacific University. She an instructor of Geometric Optics and Low Vision Rehabilitation and in 2016 began to focus her efforts on the development of endpoints for inherited retinal disease studies. Dr. Kammer also has adjunct faculty status at two universities and is currently developing a low vision department within the department of ophthalmology at University of California, Irvine. Her humanitarian work includes partnering with global charities to design and implement national clinical programs serving persons with albinism and low vision in East Africa.
Clinical & Regulatory Advisor
Ms. Niksch has 30 years of medical device industry experience in the areas of Clinical and Regulatory Affairs, with the majority of her time spent in ophthalmic device companies. Currently, Ms. Niksch serves as an independent consultant. Previously, she was Executive Director, Clinical Development Ophthalmology at Allergan. Prior to Allergan, Ms. Niksch served as VP of Clinical & Regulatory Affairs for AqueSys, Inc., which was acquired by Allergan. Prior to AqueSys, Ms. Niksch served as VP of Regulatory, Quality and Clinical Affairs at Visiogen, Inc. (acquired by Abbott) and Glaukos Corporation. Ms. Niksch obtained her BS in Biology from the University of Nevada Reno and she has an MBA from National University. Ms. Niksch is a past president of the Orange County Regulatory Affairs (OCRA) discussion group and also served as the Ophthalmic Industry Representative on the FDA's Ophthalmic Devices Advisory Panel.
Clinical Development Advisor
Dr. Schuchard is the Executive Director for the Envision Research Institute (Wichita, KS). The research program at the ERI is dedicated to investigating functional implications of vision loss, access to interventions, optimizing rehabilitation therapies, and developing accessibility technology. He previously was Senior Staff / Lead Reviewer in the CDRH at FDA. His Team Lead experiences include a broad range of innovative medical device submissions (e.g., IDE, PMA, De Novo, 510(k), 513(g), Q-Sub, EFS, and EAP) He was also a member of review teams for combination products; both device and drugs as well as device and biologics. As a researcher at Stanford University he designed and executed innovative investigational studies and evaluated pharmaceutical and device therapies for adults with or aging into visual impairments. His research portfolio ranges from studies of fundamental mechanisms causing visual impairments to FDA multi-center clinical trials (including orphan indications).
Retinitis Pigmentosa Clinical Research and Low Vision Optometry Advisor
Dr. Bittner is an optometrist who specializes in low vision rehabilitation and research. She has a PhD in clinical investigation from the Johns Hopkins School of Public Health. She is currently an Associate Professor at the UCLA Stein Eye Institute, where she is the Smotrich Family Optometric Clinician-Scientist Chair and Chief of Optometric Services. Dr. Bittner previously held faculty positions at the Johns Hopkins Wilmer Eye Institute’s Lions Low Vision Research and Rehabilitation Center in Baltimore and the Nova Southeastern University, College of Optometrye. Dr. Bittner's research interests include the psychophysical assessment of the visual system to validate tools to monitor disease and therapeutic outcomes. Dr. Bittner received NIH funding from the National Eye Institute to lead clinical studies for individuals with retinitis pigmentosa, and has served as a co-investigator or consultant for multi-center clinical trials of devices or treatments for patients with inherited retinal degenerations.
Medical Expert, Retinal Specialist
Dr. Saperstein is a board-certified ophthalmologist, vitreoretinal surgeon and entrepreneur, working in Seattle, WA. Dr. Saperstein has over 20 years’ experience in clinical medicine and drug development. He has been an investigator in over 20 clinical trials in this field. He was an NIH funded clinician-scientist at Emory University and University of Washington and holds over patents in the pharmaceutical, low vision and surgical fields. He currently sits on several scientific and clinical advisory boards and was the former Chief Medical Officer of QLT Inc, (Vancouver). In addition, he has cofounded 2 biotech ophthalmology start-up companies, Retinagenix, LLC and Zumedix, LP. Retinagenix developed a synthetic retinoid, currently in Phase II clinical trials and was recently sold to Bridgebio, Inc (Palo Alto). Zumedix is commercializing technology that dramatically improves the efficacy and spectrum of existing topical antibiotics.
Medical Expert, Retinal Specialist
Dr. Choudhry is the co-founder and medical director of the Vitreous Retina Macula Specialists of Toronto. He is an internationally recognized vitreoretinal surgeon with affiliations at both the University of Toronto and Harvard Medical School and is a faculty member at Cleveland Clinic Canada. He is a recognized thought leader in retinal imaging and the diagnosis and treatment of rare disorders of the retina and vitreous. He has published in the world’s most read/indexed journals including: The New England Journal of Medicine, the Lancet, Ophthalmology and the Retina Journal. He has served on the board of directors of the American Society of Retina Specialists (ASRS) and the CNIB diabetic retinopathy & vision loss project.
Contact firstname.lastname@example.org for more information.